Biogen (BIIB) Receivables (2009 - 2026)

Biogen has reported Receivables for 18 years, with the latest figure at $1.9 billion in Q2 2026.

• On a quarterly basis, Receivables rose 16.09% year-over-year to $1.9 billion in Q2 2026; TTM through Jun 2026 was $1.9 billion, a 16.09% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 4.44% from the prior year.
• Receivables was $1.9 billion for Q2 2026 at Biogen, up from $1.4 billion in the prior quarter.
• The five-year high for Receivables was $3.2 billion in Q3 2023, with the low at $4.4 million in Q4 2025.
• Average Receivables over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables soared 46.18% in 2022, then slumped 99.69% in 2025.
• Over 5 years, Receivables stood at $1.7 billion in 2022, then advanced by 4.49% to $1.8 billion in 2023, then dropped by 21.15% to $1.4 billion in 2024, then plunged by 99.69% to $4.4 million in 2025, then soared by 42754.55% to $1.9 billion in 2026.
• The last three Receivables figures came in at $1.9 billion (Q2 2026), $1.4 billion (Q1 2026), and $4.4 million (Q4 2025), per Business Quant data.